Obsessive-Compulsive Behaviors in Autism —Reply

In Reply Mr Ne ’eman and colleagues raise important points regarding the use of the CYBOCS-PDD in our study. Our trial aimed to investigate a biological concept and provide evidence as to whether fluoxetine could reduce obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders. Cl inicians regularly use these medications, and a Cochrane review had called for proof of their efficacy. The aim was to extend the evidence base and ultimately improve the care of young people with autism spectrum disorders. The CYBOCS-PDD was chosen because of its use in previous studies and evidenc e in this population of sensitivity to change. We also measured anxiety, aberrant and repetitive behaviors, clinical global impressions, and disruptiveness in an effort to broaden the outcome measures.
Source: JAMA - Category: General Medicine Source Type: research